ArticleBioresources and bioprocessing2026
Chitosan-mediated nano-bioprocessing of Acacia seyal seed extract for enhanced antineoplastic, anti-Helicobacter pylori and antioxidant performance.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New concepts of chitosan-based mucosal formulations for supporting control of the gastric pathogenFrontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Acacia seyal is a medicinal plant rich in bioactive compounds known for their antimicrobial, antioxidant, and anticancer properties. Conventional plant extracts often suffer from poor stability and limited bioavailability, reducing their therapeutic effectiveness. The utilization of chitosan nanoparticles (CS-NPs) offers a promising strategy to enhance biological activity of plant extracts. Encapsulation of A. seyal seeds extract (ASSE) in CS-NPs (ASSE@CS-NPs) was the aim of the present investigation to compete Helicobacter pylori and HCT116 cancer cells. The phytochemical profile of ASSE revealed diverse phenolic acids and flavonoids via HPLC analysis. Methyl gallate was dominated (20.98 mg/g), followed by gallic acid, and catechin. FTIR analysis confirmed characteristic functional groups in ASSE and CS-NPs. Peak shifts and intensity variations in ASSE@CS-NPs indicated successful encapsulation through hydrogen bonding and electrostatic interactions. ASSE@CS-NPs showed the strongest anti-H. pylori effect with inhibition zone (23.7 mm) and lowest MIC/MBC (15.62 µg/mL). Compared to CS-NPs (20.7 mm, 31.25 µg/mL) and ASSE (19.7 mm, 31.25 µg/mL). ASSE@CS-NPs showed notable antioxidant activity, achieving 96% scavenging at 1000 µg/mL with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.